A real-world retrospective study of Ruxolitinib for factors and outcomes associated with transplant-associated thrombotic microangiopathy (TA-TMA) in patients with graft-vs-host-disease
Latest Information Update: 30 Aug 2021
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Graft-versus-host disease; Thrombotic microangiopathy
- Focus Therapeutic Use
- 30 Aug 2021 New trial record
- 17 Aug 2021 Results published in the Transplantation Proceedings.